Contact
searchSearch
HMP Global
Login

Head and Neck Cancer Resource Center

Featured

News
Analyzing Billing Patterns and Medicare Reimbursement Among Otolaryngologists Performing In-Office Cerumen Removal
09/12/2022
Yvette C. Terrie, BS Pharm, RPh
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other...
09/12/2022
Journal of Clinical Pathways
News
Model Predicts Presence of Occult Nodal Metastasis Better Than Current Standard in Early-Stage Oral Cavity Squamous Cell Carcinoma
05/18/2022
Ellen Kurek
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that...
05/18/2022
Journal of Clinical Pathways
News
Decision Analytical Model Optimizes Posttreatment Surveillance Strategies Among Patients With Oropharyngeal Carcinoma
04/29/2022
Marta Rybczynski
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common...
04/29/2022
Journal of Clinical Pathways
News
Medicare Reimbursement Decreased from 2000 to 2020 in Head and Neck Surgical Oncology
04/26/2022
Ellen Kurek
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased...
04/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Imaging Use Among Patients With Head and Neck Cancer
01/28/2022
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients...
01/28/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Nivolumab vs Pembrolizumab for Head and Neck Cancer
08/18/2021
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay...
08/18/2021
Journal of Clinical Pathways
News
What Are the Costs Associated With Imaging Surveillance After Treatment for Head and Neck Cancer?
08/11/2021
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many...
08/11/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Temozolomide Use in Patients with Glioblastoma
06/02/2021
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support...
06/02/2021
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Clinical Practice Guideline for Central Nervous System Cancers
03/24/2021
Janelle Bradley
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its...
03/24/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Esophageal Cancers
03/10/2021
Janelle Bradley
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive...
03/10/2021
Journal of Clinical Pathways
Quiz
Quiz: Cetuximab vs Cisplatin for Locoregional Control of HNSCC
02/01/2021
02/01/2021
Journal of Clinical Pathways

Newsfeed

News
Analyzing Billing Patterns and Medicare Reimbursement Among Otolaryngologists Performing In-Office Cerumen Removal
09/12/2022
Yvette C. Terrie, BS Pharm, RPh
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other...
09/12/2022
Journal of Clinical Pathways
News
Model Predicts Presence of Occult Nodal Metastasis Better Than Current Standard in Early-Stage Oral Cavity Squamous Cell Carcinoma
05/18/2022
Ellen Kurek
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that...
05/18/2022
Journal of Clinical Pathways
News
Decision Analytical Model Optimizes Posttreatment Surveillance Strategies Among Patients With Oropharyngeal Carcinoma
04/29/2022
Marta Rybczynski
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common...
04/29/2022
Journal of Clinical Pathways
News
Medicare Reimbursement Decreased from 2000 to 2020 in Head and Neck Surgical Oncology
04/26/2022
Ellen Kurek
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased...
04/26/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Nivolumab vs Pembrolizumab for Head and Neck Cancer
08/18/2021
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay...
08/18/2021
Journal of Clinical Pathways
News
What Are the Costs Associated With Imaging Surveillance After Treatment for Head and Neck Cancer?
08/11/2021
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many...
08/11/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Temozolomide Use in Patients with Glioblastoma
06/02/2021
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support...
06/02/2021
Journal of Clinical Pathways
News
Deep Learning Models for Image-Guided RT in Head and Neck and Prostate Cancers
12/10/2020
Machine learning models achieve clinically acceptable accuracy in image segmentation tasks in radiotherapy planning and reduce overall contouring time for head and neck and prostate cancers.
Machine learning models achieve clinically acceptable accuracy in image segmentation tasks in radiotherapy planning and reduce overall contouring time for head and neck and prostate cancers.
Machine learning models achieve...
12/10/2020
Journal of Clinical Pathways
News
Geographic Barriers Limit CAR T-Cell Therapy Access in US Medicare Patients With DLBCL
03/12/2026
Grace Taylor, MS, MA
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in...
03/12/2026
Journal of Clinical Pathways
News
Social Drivers Linked to Hepatocellular Carcinoma Stage and Survival in US Integrated Care System
03/09/2026
Hannah Musick
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health...
03/09/2026
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab Plus Paclitaxel for Platinum-Resistant Ovarian Cancer in the US
03/06/2026
Hannah Musick
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug...
03/06/2026
Journal of Clinical Pathways
News
Real-World Data Support Earlier T-DXd Use in HR+/HER2-Low Metastatic Breast Cancer
03/04/2026
Grace Taylor, MS, MA
Earlier use of trastuzumab deruxtecan (T-DXd) in hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer was associated with longer real-world treatment duration and delayed need for...
Earlier use of trastuzumab deruxtecan (T-DXd) in hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer was associated with longer real-world treatment duration and delayed need for...
Earlier use of trastuzumab...
03/04/2026
Journal of Clinical Pathways
News
Neighborhood Socioeconomic Status Tied to Survival in US Early-Onset Metastatic Colorectal Cancer
02/19/2026
Hannah Musick
In a US community-based cohort of young adults with metastatic colorectal cancer, lower neighborhood socioeconomic status was independently associated with significantly higher mortality, highlighting the impact of structural disadvantage on...
In a US community-based cohort of young adults with metastatic colorectal cancer, lower neighborhood socioeconomic status was independently associated with significantly higher mortality, highlighting the impact of structural disadvantage on...
In a US community-based cohort...
02/19/2026
Journal of Clinical Pathways
News
Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in Metastatic TNBC
02/13/2026
Grace Taylor, MS, MA
In the phase 3 ASCENT-04/KEYNOTE-D19 trial, first-line sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival (PFS) and response durability compared with chemotherapy plus pembrolizumab in programmed...
In the phase 3 ASCENT-04/KEYNOTE-D19 trial, first-line sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival (PFS) and response durability compared with chemotherapy plus pembrolizumab in programmed...
In the phase 3...
02/13/2026
Journal of Clinical Pathways
News
Mobile App Self-Acupressure Reduces Ovarian Cancer Fatigue, Study Finds
02/13/2026
Grace Taylor, MS, MA
A mobile app–guided self-acupressure program significantly reduced cancer-related fatigue in women with ovarian cancer, with benefits sustained for up to 24 weeks.
A mobile app–guided self-acupressure program significantly reduced cancer-related fatigue in women with ovarian cancer, with benefits sustained for up to 24 weeks.
A mobile app–guided...
02/13/2026
Journal of Clinical Pathways
News
Interlocking Poverty, Stigma, and Information Gaps Drive Hospice Exclusion for Low-Income Cancer Patients
02/13/2026
Lisa Kuhns, PhD, MD
Hospice exclusion among low-income cancer patients is not the result of a single barrier but a reinforcing web of poverty, stigma, and unequal access to knowledge that systematically limits end-of-life care choices, according to study results...
Hospice exclusion among low-income cancer patients is not the result of a single barrier but a reinforcing web of poverty, stigma, and unequal access to knowledge that systematically limits end-of-life care choices, according to study results...
Hospice exclusion among...
02/13/2026
Journal of Clinical Pathways
News
Patient Navigation Improves Colorectal Cancer Screening in Washington, DC Safety Net
02/11/2026
Hannah Musick
A evaluation at a Washington, DC safety net health system found that patient navigation improved colorectal cancer screening and follow-up completion at a moderate per-patient cost.
A evaluation at a Washington, DC safety net health system found that patient navigation improved colorectal cancer screening and follow-up completion at a moderate per-patient cost.
A evaluation at a Washington, DC...
02/11/2026
Journal of Clinical Pathways
News
Tumor-Informed ctDNA Surveillance for HCC and CCA After Liver Transplant Shows High Specificity
02/09/2026
Grace Taylor, MS, MA
Personalized tumor-informed circulating tumor DNA (ctDNA) testing after liver transplantation shows high specificity but limited sensitivity for detecting recurrence in patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma...
Personalized tumor-informed circulating tumor DNA (ctDNA) testing after liver transplantation shows high specificity but limited sensitivity for detecting recurrence in patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma...
Personalized tumor-informed...
02/09/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Imaging Use Among Patients With Head and Neck Cancer
01/28/2022
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients...
01/28/2022
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use